Effect of statins on risk of coronary disease - A meta-analysis of randomized controlled trials

被引:947
作者
LaRosa, JC
He, J
Vupputuri, S
机构
[1] SUNY Hlth Sci Ctr, Off President, Brooklyn, NY 11203 USA
[2] Tulane Univ, Med Ctr, Dept Epidemiol, New Orleans, LA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1999年 / 282卷 / 24期
关键词
D O I
10.1001/jama.282.24.2340
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Lowering low-density lipoprotein cholesterol (LDL-C) is known to reduce risk of recurrent coronary heart disease in middle-aged men. However, this effect has been uncertain in elderly people and women. Objective To estimate the risk reduction of coronary heart disease and total mortality associated with statin drug treatment, particularly in elderly individuals and women. Data Sources Trials published in English-language journals were retrieved by searching MEDLINE (1966-December 1998), bibliographies, and authors' reference files. Study Selection Studies in which participants were randomized to statin or control treatment for at least 4 years and clinical disease or death was the primary outcome were included in the meta-analysis (5 of 182 initially identified). Data Extraction information on sample size, study drug duration, type and dosage of statin drug, participant characteristics at baseline, reduction in lipids during intervention, and outcomes was abstracted independently by 2 authors (J.H. and S.V.) using a standardized protocol. Disagreements were resolved by consensus. Data Synthesis Data from the 5 trials, with 30 817 participants, were included in this meta-analysis. The mean duration of treatment was 5.4 years. Statin drug treatment was associated with a 20% reduction in total cholesterol, 28% reduction in LDL-C, 13% reduction in triglycerides, and 5% increase in high-density lipoprotein cholesterol, Overall, statin drug treatment reduced risk 31% in major coronary events (95% confidence interval [CI], 26%-36%) and 21% in all-cause mortality (95% CI, 14%-28%). The risk reduction in major coronary events was similar between women (29%;95% CI, 13%-42%) and men (31%; 95% CI, 26%-35%), and between persons aged at least 65 years (32%; 95% CI, 23%-39%) and persons younger than 65 years (31%; 95% CI, 24%-36%). Conclusions Our meta-analysis indicates that reduction in LDL-C associated with statin drug treatment decreases the risk of coronary heart disease and all-cause mortality. The risk reduction was similar for men and women and for elderly and middle-aged persons.
引用
收藏
页码:2340 / 2346
页数:7
相关论文
共 45 条
[1]  
[Anonymous], 1993, Am J Cardiol, V72, P1031
[2]   Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty [J].
Bertrand, ME ;
McFadden, EP ;
Fruchart, JC ;
VanBelle, E ;
Commeau, P ;
Grollier, G ;
Bassand, JP ;
Machecourt, J ;
Cassagnes, J ;
Mossard, JM ;
Vacheron, A ;
Castaigne, A ;
Danchin, N ;
Lablanche, JM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (04) :863-869
[3]  
Bestehorn HP, 1997, EUR HEART J, V18, P226
[4]   CORONARY ANGIOGRAPHIC CHANGES WITH LOVASTATIN THERAPY - THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS) [J].
BLANKENHORN, DH ;
AZEN, SP ;
KRAMSCH, DM ;
MACK, WJ ;
CASHINHEMPHILL, L ;
HODIS, HN ;
DEBOER, LWV ;
MAHRER, PR ;
MASTELLER, MJ ;
VAILAS, LI ;
ALAUPOVIC, P ;
HIRSCH, LJ .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) :969-976
[5]   EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].
BRADFORD, RH ;
SHEAR, CL ;
CHREMOS, AN ;
DUJOVNE, C ;
DOWNTON, M ;
FRANKLIN, FA ;
GOULD, AL ;
HESNEY, M ;
HIGGINS, J ;
HURLEY, DP ;
LANGENDORFER, A ;
NASH, DT ;
POOL, JL ;
SCHNAPER, H .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :43-49
[6]  
Campeau L, 1997, NEW ENGL J MED, V336, P153
[7]   PRAVASTATIN, LIPIDS, AND ATHEROSCLEROSIS IN THE CAROTID ARTERIES (PLAC-II) [J].
CROUSE, JR ;
BYINGTON, RP ;
BOND, MG ;
ESPELAND, MA ;
CRAVEN, TE ;
SPRINKLE, JW ;
MCGOVERN, ME ;
FURBERG, CD .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (07) :455-459
[8]   Comparison of one-year efficacy and safety of Atorvastatin versus Lovastatin in primary hypercholesterolemia [J].
Davidson, M ;
McKenney, J ;
Stein, E ;
Schrott, H ;
BakkerArkema, R ;
Fayyad, R ;
Black, D .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (11) :1475-1481
[9]   Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) [J].
Davis, BR ;
Cutler, JA ;
Gordon, DJ ;
Furberg, CD ;
Wright, JT ;
Cushman, WC ;
Grimm, RH ;
LaRosa, J ;
Whelton, PK ;
Perry, HM ;
Alderman, MH ;
Ford, CE ;
Oparil, S ;
Francis, C ;
Proschan, M ;
Pressel, S ;
Black, HR ;
Hawkins, CM .
AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (04) :342-360
[10]  
DOWNS JR, 1995, AM J CARDIOL, V75, P1130